TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
PARIS and BOSTON, Nov. 03, 2016 -- Neovacs (Alternext Paris:ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announced its participation at the Jefferies 2016 London Healthcare Conference taking place November 16-17 at the Waldorf Hilton in London, UK.
This Conference is the largest healthcare meeting in Europe dedicated to companies from around the world from the biotechnology, pharmaceutical, generic, consumer health, medical technology and Healthcare Service sectors. Last year, the Jefferies conference hosted over 300 participating companies, 1,200 attendees and 3,700 business-to-business and investor meetings.
The two-day event will include concurrent tracks of company presentations, thematic panel discussions, and 1x1/small-group meetings. This global gathering of leading healthcare executives and institutional, private equity and venture capital investors will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare.
About Neovacs
Listed on Alternext Paris since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr
Contacts NEOVACS – Corporate Communication & Investor Relations Charlène Masson +33 (0)1 53 10 93 14 [email protected] Investor Relations / Financial Communications Germany – MC Services Raimund Gabriel +49-89-21-02-28-30 [email protected] Press / U.S. Inquiries – The Ruth Group Lee Roth / Joseph Green +1-646-536-7012 / 7013 [email protected] / [email protected]
